Results 51 to 60 of about 10,598 (216)

A Tumor-Agnostic NTRK (TRK) Inhibitor

Cell, 2019
Larotrectinib is a small-molecule kinase inhibitor that targets NTRK fusions that occur in multiple types of cancer. Its FDA approval represents the first instance of a treatment indication being designated "tumor-agnostic" from the outset, being based on actionable genomic insights. To view this Bench to Bedside, open or download the PDF.
Franklin W, Huang, Felix Y, Feng
openaire   +2 more sources

NTRK Fusions and TRK Inhibitors: Potential Targeted Therapies for Adult Glioblastoma

Frontiers in Oncology, 2020
IntroductionGlioblastoma multiforme (GBM) is the most common primary central nervous (CNS) system malignancy with a poor prognosis. The standard treatment for GBM is neurosurgical resection, followed by radiochemotherapy and adjuvant temozolomide ...
Yuekun Wang, Piaopiao Long, Yu Wang, Wenbin Ma   +3 more
doaj   +1 more source

NTRK Somatic Fusions and Tumor Agnostic Treatment in Pediatric Cancers

Journal of Contemporary Medicine, 2022
Neurotrophic tyrosine receptor kinase (NTRK) gene rearrangements have been recently identified and developed as one of the biomarkers that have been utilized as new targets for cancer therapy.
Emel Ünal, Sonay İncesoy Özdemir, Ayça Yağmur Şimşek   +2 more
doaj   +1 more source

[Multidisciplinary consensus on optimizing the detection of NTRK gene alterations in tumours] Consenso multidisciplinar para optimizar la determinación de alteraciones del gen NTRK

, 2021
The recent identification of rearrangements of neurotrophic tyrosine receptor kinase (NTRK) genes and the development of specific fusion protein inhibitors, such as larotrectinib and entrectinib, have revolutionized the diagnostic and clinical management
López-Ríos, Fernando, Hladun, Raquel, Garrido, Pilar, Rojo, Federico, Colomer, Ramón, de Álava, Enrique, Bautista, Francisco, Álvarez, Rosa   +7 more
core   +1 more source

Oncogenic fusions: Targeting NTRK

Critical Reviews in Oncology/Hematology
Non-Small Cell Lung Cancer (NSCLC) is responsible for the highest number of cancer-related deaths in the United States. Thankfully, advancements in the detection and targeting of gene mutations have greatly improved outcomes for many patients. One significant mutation driving oncogenesis in various cancers, including NSCLC, is the neurotrophic tyrosine
Garo Hagopian, Misako Nagasaka
openaire   +2 more sources

Isolated Leptomeningeal Progression in a Patient with NTRK Fusion+ Uterine Sarcoma: A Case Report

Case Reports in Oncology, 2021
While neurotrophic tropomyosin receptor kinase (NTRK) fusions represent rare oncogenic drivers (<1% of solid cancers), the recent approval of NTRK inhibitors (larotrectinib and entrectinib) led to dramatic responses in patients with NTRK fusion ...
Tyler Lanman, Melanie Hayden Gephart, Nam Bui, Angus Toland, Seema Nagpal   +4 more
doaj   +1 more source

Use of Diagnostic Algorithms for *NTRK* Fusion-Positive Tumors in Pathology Institutes in Switzerland

healthbook TIMES. Oncology Hematology, 2021
In May 2020, larotrectinib (Vitrakvi^®^) was approved as the first tumor-agnostic agent in Switzerland for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (*NTRK*) gene fusion.
Holger Moch, Gieri Cathomas, Milo Frattini, Wolfram Jochum, Erik Vassella, Laurence de Leval, Joachim Diebold, Christian Britschgi, Thomas McKee, Lukas Bubendorf   +9 more
doaj   +2 more sources

MLH1/PMS2 Expression Could Tell Classical NTRK Fusion in Fluorescence In Situ Hybridization Positive Colorectal Carcinomas

Frontiers in Oncology, 2021
To gain insight into the clinicopathologic profile of colorectal carcinomas harboring oncogenic NTRK fusions based on eastern populations as well as make the best testing algorithm for the screen, we use pan-Trk immunohistochemistry (IHC), fluorescence ...
Yao Fu, Zheng Li, Fuping Gao, Jun Yang, Hongyan Wu, Biao Zhang, Xiaohong Pu, Xiangshan Fan   +7 more
doaj   +1 more source

Five-Year Trends in Biomarker Testing and Targeted Therapy for NSCLC: A Patient-Initiated Nationwide Survey in Japan. [PDF]

Cancer Sci
This nationwide survey reveals that comprehensive multigene testing for advanced NSCLC has rapidly expanded in Japan, steadily increasing the use of targeted therapies for rare oncogenic drivers. Despite these diagnostic advancements, approximately 30% of patients consistently remain untested, highlighting a persistent clinical gap in real‐world ...
Ikeda S, Hasegawa K, Takahama T, Kachi K, Yanagisawa A, Kawakami S, Yoshida M, Sakai M, Watanabe S, Nakagawa K.   +9 more
europepmc   +2 more sources

Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC

, 2022
The Entrectinib in NTRK+ Solid Tumours and ROS1+ NSCLC Adis Drug Evaluation video abstract, script and image slide deck provide a brief overview of the mechanism of action of entrectinib in NTRK+ solid tumours and ROS1+ NSCLC, the administration regimen ...
James E. Frampton (4995257)
core   +1 more source